US11186564B2ActiveUtilityA1
Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
Est. expiryAug 4, 2036(~10.1 yrs left)· nominal 20-yr term from priority
C07D 211/42C07D 311/58C07D 221/20C07D 249/12C07D 213/81C07D 295/104C07D 207/36C07D 403/06C07D 295/088A61P 25/18C07D 491/20C07D 417/04C07D 513/04C07D 405/12A61P 25/28C07D 413/08C07D 401/14C07D 471/10C07D 211/44C07D 207/12C07D 487/10C07D 491/107C07D 471/08C07D 491/048C07D 401/12C07D 217/24C07D 235/12C07D 311/08C07D 413/06C07D 277/66C07D 401/08C07D 307/83C07D 401/06C07D 265/30C07D 211/58C07D 223/08C07D 295/027C07D 295/073C07D 241/04C07D 405/06C07D 267/10C07D 243/08C07D 295/096C07D 295/108C07D 275/04C07D 471/04C07D 311/22C07D 237/14
41
PatentIndex Score
0
Cited by
16
References
11
Claims
Abstract
Compounds of formula I:are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A compound of formula I
wherein
Q is piperidine attached to L 1 at a nitrogen, wherein substituents, when present, are selected from the group consisting of halogen, hydroxy, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, and oxo;
R A is selected from the group consisting of (1) an optionally substituted bicyclic carbocycle containing an aromatic 6-membered ring and a non-aromatic 5-membered ring; and (2) an optionally substituted, bicyclic heterocycle selected from the group consisting of a cyclopenta[b]pyridine, a dihydrobenzofuran, a dihydrofuro[3,2-b]pyridine, a cyclopenta[c]pyridine, an indoline, a pyrrolo[3,4-b]pyridine, and an isoindoline;
L 1 is —(CH 2 CHR 1 )—, wherein R 1 is hydrogen or methyl;
L 2 is —O—; and
R B is an optionally substituted aromatic carbocycle wherein substituents, when present, are selected from the group consisting of halogen, cyano, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )oxaalkyl, —C(═O)NH 2 , and di(C 1 -C 6 )alkylamino.
2. A compound according to claim 1 wherein R A is an optionally substituted bicyclic carbocycle containing an aromatic 6-membered ring and a non-aromatic 5-membered ring.
3. A compound according to claim 1 wherein R A is an optionally substituted bicyclic heterocycle selected from the group consisting of a cyclopenta[b]pyridine, a dihydrobenzofuran, a dihydrofuro[3,2-b]pyridine, a cyclopenta[c]pyridine, an indoline, a pyrrolo[3,4-b]pyridine, and an isoindoline.
4. A compound according to claim 1 wherein L 1 is —CH 2 CH 2 —.
5. A compound according to claim 1 wherein R A is selected from the group consisting of indane, dihydrobenzofuran, 3-methyldihydrobenzofuran, methylindane, haloindane, cyanoindane, and methoxyindane.
6. A compound according to claim 1 wherein R B is selected from the group consisting of benzene, halobenzene, methylbenzene, dimethylbenzene, and methoxybenzene.
7. A compound according to claim 1 wherein the piperidine Q is unsubstituted or is substituted with one or two methyls.
8. A compound according to claim 1 wherein R A is indane.
9. A compound according to claim 1 wherein R B is halobenzene.
10. A compound according to claim 1 wherein R B is dimethylbenzene.
11. A compound according to claim 1 selected from the group consisting of:
171
172
173
174
175
176
177
178
185
186
187
188
189Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.